MHP
STLN

Manatuck Hill Partners’s Starling Oncology STLN Stock Holding History

Manatuck Hill Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44M Buy
+450,000
New +$1.89M 0.81% 41
2025
Q4 		– Sell
-629,800
Closed -$2.2M – 125
2025
Q3 		$2.2M Buy
629,800
+380,000
+152% +$1.3M 0.73% 50
2025
Q2 		$512K Sell
249,800
-100,200
-29% -$251K 0.19% 98
2025
Q1 		$399K Buy
+350,000
New +$271K 0.18% 85

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Manatuck Hill Partners's STLN Position: Q2 2026 in Review

Manatuck Hill Partners opened a new position in Starling Oncology (STLN) in Q2 2026: 450,000 shares worth $2.44M. The stake represents 0.81% of the portfolio and ranks #41 among its holdings. This is a return to the name: Manatuck Hill Partners previously reported a position in STLN as recently as Q3 2025.

Manatuck Hill Partners first reported a position in STLN in Q1 2025 and has held it in 4 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Manatuck Hill Partners held 450,000 shares of Starling Oncology worth $2.44M as of Q2 2026.
  • Starling Oncology was a new Manatuck Hill Partners position in Q2 2026.
  • Starling Oncology made up 0.81% of Manatuck Hill Partners's portfolio in Q2 2026, its #41 holding.
  • Manatuck Hill Partners first reported a position in Starling Oncology in Q1 2025 and has held it in 4 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Manatuck Hill Partners's 13F filing for Q2 2026, filed 14 Aug 2026.